塞来昔布
上皮-间质转换
癌症研究
化学
间充质干细胞
癌细胞
MAPK/ERK通路
细胞凋亡
乳腺癌
转移
癌症干细胞
药理学
细胞生长
细胞生物学
癌症
作者
Juan Carlos Gallardo-Pérez,Alhelí Adán-Ladrón de Guevara,Marco Antonio García-Amezcua,Diana Xochiquetzal Robledo-Cadena,Silvia Cecilia Pacheco-Velázquez,Javier Alejandro Belmont-Díaz,Jorge Luis Vargas-Navarro,Rafael Moreno-Sánchez,Sara Rodríguez-Enríquez
标识
DOI:10.2174/0929867328666211005124015
摘要
Drug resistance and invasiveness developed by breast cancer stem cells (BCSC) are considered the major hurdles for successful cancer treatment. Objective: As these two processes are highly energy-dependent, the identification of the main ATP supplier required for stem cell viability may result advantageous in the design of new therapeutic strategies to deter malignant carcinomas. Methods: The energy metabolism (glycolysis and oxidative phosphorylation, OxPhos) was systematically analyzed by assessing relevant protein contents, enzyme activities and pathway fluxes in BCSC. Once identified the main ATP supplier, selective energy inhibitors and canonical breast cancer drugs were used to block stem cell viability and their metastatic properties. Results: OxPhos and glycolytic protein contents, as well as HK and LDH activities were several times higher in BCSC than in their parental line, MCF-7 cells. However, CS, GDH, COX activities and both energy metabolism pathway fluxes were significantly lower (38-86%) in BCSC than in MCF-7 cells. OxPhos was the main ATP provider (>85%) in BCSC. Accordingly, oligomycin (a specific and potent canonical OxPhos inhibitor) and other non-canonical drugs with inhibitory effect on OxPhos (celecoxib, dimethylcelecoxib) significantly decreased BCSC viability, levels of epithelial-mesenchymal transition proteins, invasiveness, and induced ROS over-production, with IC50 values ranging from 1 to 20 µM in 24 h treatment. In contrast, glycolytic inhibitors (gossypol, iodoacetic acid, 3-bromopyruvate, 2-deoxyglucose) and canonical chemotherapeutic drugs (paclitaxel, doxorubicin, cisplatin) were much less effective against BCSC viability (IC50> 100 µM). Conclusion: These results indicated that the use of some NSAIDs may be a promising alternative therapeutic strategy to target BCSC.
科研通智能强力驱动
Strongly Powered by AbleSci AI